A two-carbon difference
THC carries a five-carbon side chain, called a pentyl tail. THCV carries a three-carbon propyl tail. Everything else about the molecules is the same.
Shortening the tail by two carbons changes how the molecule sits in the CB1 binding pocket. It still fits, but it no longer activates the receptor the way THC does at ordinary doses. Instead it occupies the site and blocks it. Push the dose high enough and the behavior flips: THCV begins acting as an agonist and produces effects closer to a short, sharp THC.
The plant makes THCV from a different starting acid. Most cannabinoids descend from CBGA, built with hexanoic acid. The varin cannabinoids, THCV and CBDV, descend from CBGVA, built with butyric acid instead. This is a separate biosynthetic branch, not a modification of the main one.
The appetite research, stated accurately
The claim you will see on packaging is that THCV suppresses appetite. The claim that supports it is narrower than the packaging suggests.
In rodent work published in the late 2000s, THCV reduced food intake and body weight in mice, consistent with what CB1 blockade would predict. CB1 activation drives appetite, which is the mechanism behind THC-induced hunger, so a CB1 antagonist reducing appetite is a coherent result rather than a surprising one.
A 2016 randomised trial by Jadoon and colleagues at the University of Nottingham tested THCV in 62 people with type 2 diabetes over thirteen weeks. It found improvements in fasting plasma glucose and pancreatic beta-cell function. It did not find significant appetite or weight effects in that population.
So the honest summary is that CB1 antagonism is a well-supported mechanism, the animal appetite data is real, and the human data is one small trial that measured something else. Anyone selling THCV as a weight loss product is well past what has been shown.
Why it is expensive and rare
Most industrial hemp contains THCV in trace amounts, often under 0.1%. The genetics that carry meaningful THCV are landrace varieties from southern and central Africa, which are not what the American hemp supply is built from.
That leaves two production routes. Grow specialized genetics, which means low yields and a supply chain that barely exists in Colorado. Or convert from another cannabinoid in a lab, which raises a compliance question: a converted cannabinoid is not the same regulatory object as a plant-extracted one, and the 2025 Hemp Act treats synthesis explicitly. Either route puts THCV among the most expensive cannabinoids per milligram on the shelf.
What we carry
We have carried a THCV tincture and do not have it published right now. THCV supply is inconsistent enough that we would rather not list a product we cannot reliably restock.
If you are looking for daytime cannabinoid support and THCV is not available, CBG is the closer substitute, and we do stock it. It is a different molecule with a different mechanism, so it is a substitute in use rather than in pharmacology.